Our work describing the development of a potent epigenetic editor targeting human #PCSK9 for durable reduction of LDL-C is out in @NatureMedicine today!
Cc: @chromamedicine@nchromabio
1/9
https://t.co/cnelNtMT0W
Presented at #TLM26:
A single dose of an siRNA targeting liver expression of 𝘊𝘐𝘋𝘌𝘉 was associated with a reduction in liver fat of 58 to 80% at week 36 after treatment in persons with metabolic dysfunction–associated steatotic liver disease. Full trial results: https://t.co/gQfFsMwWG2
@AASLDtweets
New paper in @NatureMedicine with @KimmieNgMD and @AnaAndersonlab! Early-onset colorectal cancer (#EOCRC) is rising. Our single-nucleus atlas of 189 tumors reveals age-associated differences and offers a resource for further research.
https://t.co/JEEAtbveWg
We are looking to hire post-doctoral fellows to work on somatic mosaicism, regeneration, and cancer development, please reach out to me if you are interested! @CRI_UTSW
Exciting day for DNA Typewriter w/ 2 papers from the lab & SeaHub out today :)
1. Mouse lineage from E0 to E13.5
https://t.co/wTVo9mHQ5P
2. A fluctuation test for gastruloid heterogeneity
https://t.co/hkXNM9lgZK
Paper #1 covered in quoted thread. More on paper #2 here. 1/n
Approved chronic #HepatitisB therapies rarely result in functional cure.
🥼 Scientists at @nchromabio are tackling this with CRMA-1001; it employs an optimized epigenetic silencer and preclinical findings support its potential for a finite treatment course and functional cure.
Read more in the #OpenAccess article published in @natBME: https://t.co/cuHKz8kdgo
What triggers growth in rare disease prevalence: a case study perspective
A rare disease market can grow without the disease becoming more common. Trials, treatments and better reporting can reveal patients who were already there.
So excited to be part of this incredible work out today in @ScienceMagazine on how P-selectin-targeted anti-senescence nanotherapy can fight fibrotic conditions and cancers. Congrats to @LoweLabMSKCC and @hellerlab members and others @MSKCancerCenter!! https://t.co/IMPeM3VM5h
At @CellularIntelHQ, we're building a universal foundation model of cell signaling to understand, predict and ultimately control how cells behave.
Grateful to welcome @ylecun, Bob Langer, Jens Nielsen and @fabian_theis to our Scientific Advisory Board.
https://t.co/WOrECjnoIl
Today we officially welcome Yann LeCun (@ylecun), Bob Langer, Jens Nielsen and Fabian Theis (@fabian_theis) to the Cellular Intelligence Scientific Advisory Board. Langer also joins our Board as an observer.
Four people who have changed what is possible in AI, biology and medicine, now working with us to learn the rules that govern how cells change, and carry that knowledge into medicine.
@FortuneMagazine's @CatGioino has the story: https://t.co/sCZH6rKKfA
Proud to see this work out today in @natBME, describing the development of an epigenetic editor for chronic hepatitis B. Congrats to the X-less Yesse Anglero-Rodriguez, John Xiong, and all who contributed @chromamedicine -> @nchromabio
https://t.co/Illw8MNaFB